SEC Info - Eli Lilly & Co. - ‘8-K’ for 4/27/23

SEC Info℠

Home

Help

Please Sign In

Eli Lilly & Co. – ‘8-K’ for 4/27/23

On: Thursday, 4/27/23, at 7:02am ET · For: 4/27/23 · Accession #: 59478-23-160 · File #: 1-06351

  As Of               Filer                 Filing    For·On·As Docs:Size

 4/27/23  Eli Lilly & Co.                   8-K:2,9     4/27/23   12:563K

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     70K 
 2: EX-99.01    Miscellaneous Exhibit                               HTML    214K 
 7: R1          Cover Page                                          HTML     72K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- lly-20230427_htm                    XML     58K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      9K 
 4: EX-101.DEF  XBRL Definitions -- lly-20230427_def                 XML     50K 
 5: EX-101.LAB  XBRL Labels -- lly-20230427_lab                      XML    114K 
 6: EX-101.PRE  XBRL Presentations -- lly-20230427_pre               XML     51K 
 3: EX-101.SCH  XBRL Schema -- lly-20230427                          XSD     17K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               17±    23K 
12: ZIP         XBRL Zipped Folder -- 0000059478-23-000160-xbrl      Zip     48K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

lly-20230427

i 0000059478 i false00000594782023-04-272023-04-270000059478us-gaap:CommonClassAMember2023-04-272023-04-270000059478lly:A718NotesDueJune12025Member2023-04-272023-04-270000059478lly:A1.625NotesDueJune22026Member2023-04-272023-04-270000059478lly:A2.125NotesDueJune32030Member2023-04-272023-04-270000059478lly:A625Notesdue2031Member2023-04-272023-04-270000059478lly:A500NotesDue2033Member2023-04-272023-04-270000059478lly:A6.77NotesDueJanuary12036Member2023-04-272023-04-270000059478lly:A1625NotesDue2043Member2023-04-272023-04-270000059478lly:A1.700Notesdue2049Member2023-04-272023-04-270000059478lly:A1125NotesDue2051Member2023-04-272023-04-270000059478lly:A1375NotesDue2061Member2023-04-272023-04-27


			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): i April 27, 2023

i ELI LILLY AND COMPANY

(Exact Name of Registrant as Specified in its Charter)

i Indiana

i 001-06351

i 35-0470950

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

i Lilly Corporate Center

i Indianapolis,

i Indiana

i 46285

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: ( i 317) i 276-2000

Not Applicable

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):


i ☐						Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


i ☐						Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


i ☐						Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


i ☐						Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

i Common Stock (no par value)

i LLY

i New York Stock Exchange

i 7 1/8% Notes due 2025

i LLY25

i New York Stock Exchange

i 1.625% Notes due 2026

i LLY26

i New York Stock Exchange

i 2.125% Notes due 2030

i LLY30

i New York Stock Exchange

i 0.625% Notes due 2031

i LLY31

i New York Stock Exchange

i 0.500% Notes due 2033

i LLY33

i New York Stock Exchange

i 6.77% Notes due 2036

i LLY36

i New York Stock Exchange

i 1.625% Notes due 2043

i LLY43

i New York Stock Exchange

i 1.700% Notes due 2049

i LLY49A

i New York Stock Exchange

i 1.125% Notes due 2051

i LLY51

i New York Stock Exchange

i 1.375% Notes due 2061

i LLY61

i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated April 27, 2023, announcing the financial results of Eli Lilly and Company for the quarter ended March 31, 2023.

Item 9.01. Financial Statements and Exhibits.


Exhibit No.			Description
99.1			Press Release of Eli Lilly and Company, dated April 27 , 2023.
104			Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



ELI LILLY AND COMPANY
(Registrant)

By:						/s/ *Donald A. Zakrowski*
Name:						Donald A. Zakrowski
Title:						Senior Vice President, Finance, and Chief Accounting Officer
Date:						April 27, 2023

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	4/27/23
	3/31/23	4
		List all Filings

↑Top

Filing Submission 0000059478-23-000160 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Eli Lilly & Co. – ‘8-K’ for 4/27/23

On: Thursday, 4/27/23, at 7:02am ET · For: 4/27/23 · Accession #: 59478-23-160 · File #: 1-06351

Previous ‘8-K’: ‘8-K’ on / for 3/17/23 · Next: ‘8-K’ on 5/4/23 for 5/1/23 · Latest: ‘8-K’ on 2/9/24 for 2/7/24

Current Report — Form 8-KFiling Table of Contents

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Current Report — Form 8-K

Filing Table of Contents